Q3 2019 Earnings Call
Thank you for your patience.
An answer session to ask a question during the session you will need press star one on your telephone.
Please be advised that today's conference is being recorded if you require any further assistance. Please press star zero I would now like to hand, the conference over to your speaker today, how long O'donnell. Thank you. Please go ahead.
Thank you operator, and good morning, everyone. Thank you for joining us on today's call.
Our speakers today or Michael Stubblefield, President Chief Executive Officer, Aecoms, Klocek Executive Vice President and Chief Financial Officer, The press release and a presentation accompanying this call are available on our Investor website, <unk> IR dot event or sciences Dot com.
A replay of this webcast will also be available on our website. Following this call.
Following our prepared remarks, well open the lineup for questions.
I'd like to note that we will be making some forward looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate may occur in the future. These forward looking statements are subject to a number of risks or uncertainties, including those set forth in or Assisi filings actual results might differ materially from any forward looking.
Statements that we make today. These forward looking statements speak only as of today, but they are made.
We do not assume any obligation to update these forward looking statements whether as a result of new information future events and developments or otherwise. This call will include a discussion of non-GAAP measures. A reconciliation of these non-GAAP measures can be found in the appendix to the presentation with that I will now turn the call over to Michael.
Thank you Alan and good morning, everyone. We appreciate you joining our third quarter earnings call.
Let's get right into the performance for the quarter I'm on slide three.
Organic revenue growth was 2.4% for the period, which reflected a couple of factors.
First our strong growth in the Biopharma end market container in the quarter, we were up 7% on organic basis and are up 10% for the year.
You may recall that ball former represents approximately 50% of our annual revenues and continued momentum in this end market is a critical element of our model.
This growth was partially offset by low single digit decline in education and government.
Which had significant growth in 2018, driven by the initiation of a new customer contract.
Tom will share more details later, but this contract affected the year over year comparison by more than 200 basis points.
Turning to adjusted EBITDA, we continue to make excellent progress on managing product pricing relative to product cost inflation and delivering the synergies from the VW our acquisition.
However, the positive impact of these factors was offset by foreign currency headwinds and adverse product mix, which together diluted margins by approximately 100 basis points in the quarter.
The one off issue in education and government that I mentioned previously also contributed to the margin performance.
We will provide more details in a few minutes, but we are confident that our long term growth and margin expansion model is intact.
Q3 was an excellent quarter for earnings growth as our adjusted earnings per share increased 49%.
Driven by our operating performance and the ongoing benefits on interest expense from our de leveraging.
We remain on track to deliver adjusted earnings in the range of 55 to 58 cents per share for the full year.
It was also an outstanding quarter for cash flow generation and continued de leveraging.
Our unlevered free cash flow in the quarter was 206 million.
Representing 127% of adjusted net income.
Working capital was the main contributor to the free cash flow improvement.
Net leverage declined to 4.8 times in the quarter down from five times at the end of the second quarter and from seven times at the beginning of the year.
In addition to the impact from the IPO earlier this year, we're on track to reduce leverage through operational performance for almost the full turn this year.
Well, we're pleased with the progress we made in the quarter. There were some notable headwinds worth mentioning.
The quarter started off somewhat slow and we saw modest tightening and capital expenditures, particularly in Europe .
Industrial end markets, which represent approximately 25% of our revenue also continues to be soft around the world.
Despite these challenges and excluding the onetime impact we encountered in our education and government end market.
We were able to deliver mid single digit growth in our core business.
Also we were encouraged by the momentum of our business in September that has carried forward into the fourth quarter.
Our exposure to biopharma, including the high profile production space, our global presence broad customer access and a highly recurring revenue profile make for a resilient model that performs well across economic cycles.
Hi, moving to slide four we're on the left you can see highlighted the sales growth synergy execution adjusted EPS growth and continued balance sheet de leveraging that I previously discussed.
I would like to take a minute to cover some non financial highlights.
We were pleased to expand our share of wallet with several existing biopharma customers.
One. Notable example is an existing account, which we previously only served in Europe .
After understanding the value our integrated offering brought to its European business. This global Biopharma customer decided to expand the contract on a worldwide basis.
We also won multiyear contract extensions with several top tier biopharma accounts and successfully on boarded several new customer accounts, including some important wins and see our ROE and education space.
During the quarter, we began work to expand our innovation center in Bridgewater, New Jersey.
Nearly doubling our footprint, we'll be adding capabilities to support our customers in the areas of downstream processing and cell and gene therapy.
We also began work to increase production capacity for high purity low endotoxin sugars used in both the upstream and downstream workflows are the biologics manufacturing process.
We anticipate that this new capacity will be online by the end of 2020.
Our digital offering remains a key driver for our business model and continually enhancing user experience is a priority.
We implemented additional improvements throughout the third quarter and see additional online traffic leading to revenue growth across our platform.
The.
Number we announced that beyond Hoffman, the leader of our manufacturing and procurement teams plans to step down from a bond for later this year to join New Mountain capital, our private equity sponsor who continues to own approximately 20% of the company.
During its been a Bible member of our executive team for the past five years and we appreciate his contributions to our growth and execution.
The good news is up you on will be with us for as long as we need him and will be available to us even after his official transition.
With the Orange departure, we're pleased to welcome Tom Your Fox, who recently joined as Executive Vice President Global operations in supply chain.
Tony brings a wealth of experience in supply chain management from her prior roles at Johnson, and Johnson as well as that Avon Walmart and Ford.
Her leadership and experience will be critical in helping us build a fully integrated end to end supply chain that will further strengthen our overall value proposition to our customers around the world.
With that let me turn it over to Tom.
Thank you Michael I'm on slide five where you can see the 2.4% organic growth and the breakdown by region. The quarter was a bit lumpy with low single digit growth in July and low single digit contraction in August . However, we were pleased to see this trend reverse in September when growth returned to the mid single digit levels. It is important to note the choice.
LNG comparisons we had in the quarter, considering the 9% organic growth we had in the third quarter of 2018.
1% growth in the Americas stands out as this is where the effect of the 2018, one off that Michael mentioned materialized for this single account in the education and government space, we had more than $40 million of sales in the third quarter of 2018, reflecting the ramp up at the start of this new contract in 2019, a large portion of that.
Revenue for this contract was recognized in the second quarter. Additionally, not all the Q3 2018 volume repeated as some portion of the ramp up was to establish a threshold level of inventory to service the business absent. This factor the Americas growth would have exceeded 4% in the quarter and the growth for the entire company would have approximated 5%.
Europe was strong at 4.5% with growth across all of our end markets, including high single digit growth in Biopharma ammonia at 8% grew a bit more modestly than we've seen recently, although biopharma reported low double digit growth and we had a very strong month in September growing well into the double digits, Let me move.
Slide six for a very quick look at sales by end market and product group as you can see Biopharma grew in the high single digits, well health care and advanced technologies and applied materials were flat education and government. As previously noted had a low single digit decline by product group proprietary materials and consumables declined low so.
Single digits, which in large part reflected the Americas education and government one off we've been describing I will talk more about this product group when covering our adjusted EBITDA performance third party materials and consumables grew mid single digits, the services and specialty procurement group grew by low double digits and the equipped.
And then instrumentation group grew low single digits, where we saw customers moderate capital expenditures.
Slide seven as a summary of our adjusted EBITDA free cash flow and adjusted EPS performance as Michael indicated, we did well on product pricing versus product cost inflation and on synergy realization, but had about 100 basis points of dilution from adverse foreign exchange and mix I will cover this in more detail.
On the next slide cash flow in the quarter with strong Unlevered free cash flow was 206 million up 48% and is up 34% for the year to date, our leverage position continues to improve as we ended the quarter at 4.8 down for approximately five times at the end of the second quarter.
We expect to see further progress in the fourth quarter last the 49% increase in our adjusted earnings per share reflects the operational performance and the ongoing benefits on interest expense from our deleveraging.
Slide eight shows the adjusted EBITDA Bridge from the third quarter of 2018 to the third quarter of 2019.
Starting with the 13.7 million price volume factor, we had flat volume in the quarter, reflecting the netting of some very strong growth in biopharma against the negative impact of the one off in our Americas education and government business.
Single use and serum volumes in the Americas were particularly strong.
Product pricing relative to product cost inflation performance was also strong, particularly in the Americas. This was offset by timing of supplier and customer rebates. The productivity factor reflects our continued realization of the S. DNA synergies from the VW our acquisition around 9 million in the quarter largely offset.
By non Cogs inflation, and approximately 5 million in strategic investments.
These investments are mostly targeted to customer facing sales and marketing functions.
And to new supply chain facilities to support growth in the EMEA region.
Sales mix had an adverse impact in the quarter, but it's something we view as temporary in nature.
Part of our margin enhancement strategy is to drive the sales of our proprietary products, which are accretive to margins. We have been very successful in doing this and in fact for the six quarters preceding this quarter the sales growth rate for proprietary products had exceeded the sales growth rate for third party products, but in the case of this.
Third quarter sales for our proprietary products were down as I mentioned earlier, the one off sales decline in the Americas education and government business was the main factor here. This customer volume is largely comprised of proprietary products.
Similarly in the Americas, we experienced a normalization in sales of proprietary materials to the health care space compared to the third quarter of 2018 when sales of these materials grew 25%.
Foreign currency is the last bridge item I want to cover we've been experiencing foreign currency headwinds all year. The impact was the most intense in the first quarter. When for example, we were comparing the 2018 Euro exchange rate of 123 to 2019 at 114, a nine cents gap at that time.
For the third quarter. This difference was down to five cents. So 116 versus 111, but it's still created a $6 million year over year headwind for us. We expect this impact to narrow further in the fourth quarter, combining the 6 million dollar FX impact in the $9 million mix impact, we realized an approximate 100 basis point contraction in.
Margins from 2018. This is not something we expect to continue.
Slide nine has our segment results as I indicated earlier, the 1% organic revenue growth rate in the Americas exceeded 4% absent the one off revenue decline in education and government business. We also exited the quarter with mid single digit growth for the month of September .
We enjoyed another solid quarter for the Biopharma business, our largest customer group with sales up mid single digits, reflecting new customers and strong volume growth from customer spending on research and development. The Bioproduction business also remained strong with low double digit growth.
This strength was partially offset by a mid single digit contraction in health care, which reflected the normalization I mentioned earlier in sales of proprietary materials to the healthcare space absent the normalization from this customer Q3 sales for America's healthcare would've been up 3%.
We experienced mid single digit contraction in education and government apart from the one off item, we actually experienced improved performance in the remainder of this end market, especially in higher education, where we had some recent customer wins, the advanced technologies and applied materials end market was down low single digits driven by high single digit.
Decreases from food and beverage agriculture, semiconductor and chemical customers, reflecting softness in the industrial sector. This was partially offset by growth in our aerospace and defense platforms.
Despite the more challenging revenue comparison, the Americas region reported an improvement in the management EBITDA margin rate, which reflected strong product pricing relative to product cost inflation and ask DNA savings driven by the VW, our synergies and lower incentive compensation accruals.
These were partially offset by the adverse mix factors and timing of customer rebates that I referenced in the overall adjusted EBITDA margin bridge.
In Europe net sales increased approximately 4.5% on an organic basis with roughly equal contributions from improved pricing and volume growth sales to the Biopharma end market increased high single digits from broad based strength across strategic customer accounts and new customer wins the healthcare.
Sure segment experienced mid single digit growth largely due to strong sales of proprietary materials, partially offset by declines in third party consumables and equipment and instrumentation products.
Sales to education and government consumers grew in the low single digits were successful in winning new government projects, but these gains were partially offset by contraction and equipment and instrumentation sales advanced technologies and applied materials recorded low single digit growth driven by higher sales of third party materials and can.
Tools and relatively flat sales and electronic materials.
Europe had a modest improvement in the management EBITDA margin rate, we had strong product pricing relative to product cost inflation performance modest volume leverage of favorable mix of sales and SGN a savings driven by the VW, our synergies and lower incentive compensation accruals offsetting these were the unfavorable transaction.
I will foreign currency headwinds and the timing of supplier rebates.
The AMEA region reported organic sales up 8.2% due to growth in Biopharma and advanced technologies and applied materials. Our two largest end markets, we exited the quarter with over 30% growth for the month of September .
The bio pharma business experienced low double digit growth driven by increased volume and lab products, primarily through sales of third party materials and consumables. These were partially offset by a decline in sales to biopharma production customers driven by challenging prior year comparisons and the timing of customer production campaigns offset by.
A stronger sales of single use offerings.
Vance technologies in applied materials experienced mid single digit growth driven by sales of third party materials and consumables.
Sales of electronic materials were flat year over year.
May I had a decline in the management EBITDA margin rate from 24% in 2018% to 20% in 2019, we had modest volume leverage offset by slightly dilutive mix of product sales and investments in customer facing sales and marketing functions and new supply chain Facil.
For future growth.
Turning to slide 10, I want to share some more detail on cash performance for the quarter for grounding the green bars on the left show free cash flow, which grew from $99 million in the third quarter of 2018 to 185 million in the third quarter of 2019 net working capital contribute approximately 80 million of this 80.
6 million dollar improvement as you can see in the table on the right. We're clearly getting some traction from the leadership attention. This areas receiving however, we still have an opportunity for significant further improvement. You'll also note that the improvement in free cash flow is from lower interest costs, driven by our deleveraging was largely offset by higher paying.
That's for income taxes, as our net operating loss deductions begin to expire.
Excluding cash interest, which is shown in the blue bars. The unlevered free cash flow grew from 139 million in 2000 $18 million to $206 million in 2019. This cash generation enabled approximately 157 million of cash deleveraging in the quarter.
Speaking of de leveraging slide 11 gives a quick update on leverage at the end of the quarter. We started the year at seven times and reduced it to five times by the end of June and further reduced it in the third quarter to 4.8 times, we expect our leverage ratio to approximate four and a half times by year end and continue to.
Targeting a long term leverage ratio in the range of two times. The four times looking ahead, there are some opportunities with our debt structure to further reduce the interest burden in particular, our 2 billion in senior unsecured debt with a 9% coupon and our 1.5 billion in senior secured debt with a 6% coupon offer.
Attractive opportunities for refinancing in the second half 2020, we will share more detail as we get closer to that date.
Our full year revenue and earnings guidance is on slide 12, we're adjusting our full year outlook to reflect the third quarter performance and foreign currency differences between our original guidance and the current environment.
We now expect full year revenues to be in the range of 6.02 to 6.08 billion with organic growth of 5% to 6%.
Adjusted EBITDA in the range of 1.0 to five to 1.035 billion or an increase of 8.4% to 9.4% at the midpoint. The new guidance reflects a 1% reduction in revenues and a reduction in adjusted EBITDA of approximately 2%.
Our guidance for adjusted earnings in the range of 55 cents to 58 cents per share or an increase of 52% to 60% remained unchanged.
With the updated guidance, we expect a very strong fourth quarter.
With inferred sales growth of 5% to 6% EBITDA margin expansion in excess of 100 basis points and adjusted EPS growth of 57% to 87%.
I will now I'll turn it over to the operator to begin the question and answer section.
Thank you as a reminder, chaska question you will need to press star one on your telephone to withdraw your question press the pound or hash key pre standby will weaken pilots you in a roster.
And our first question comes from the line of Taco Peterson from JP Morgan Your line is open.
Hey, thanks.
Tom I want to go back to kind of how the quarter played out if we go back to September you had made some comments European soften that ended up being fine and Conversely, with the Americas that came in a little bit light again.
Can you kind of knew about so can you talk a little bit about where you're feeling better worst geographically coming out of the quarter were you surprised at the reversal in Europe and able to talk at all about October trends I know you said September was really strong.
Yes, so happy to take that 90 Tyco.
Just just starting with Q3 the or the.
We look at the growth by month, it's kind of interesting we were.
I think I try to say the comments, we were kind of in that three percentish range.
Month in July and we actually went negative in August and no. It was in part and.
In Europe , where we were seeing that.
And the vintage the month of August is tough always to.
Kind of base of full year projection on given schedules and vacation, particularly in Europe .
But we definitely were sounding a cautionary tone after seeing that but I'd say that September was very strong for us across the board meeting the.
The Americas was.
Mid single digits.
Europe was high single digits and.
In Asia as I said was well into double digits, so very strong.
Month of September in terms of October were not.
Close yet but.
We are trending in line with.
Well the guidance that that we provided for the full year as well as what that implies for the fourth quarter. So they off to a reasonably good start for for the quarter and it's going to that it's going to be pretty strong quarter relative to Q3.
And then on Asia was a little surprised that EMEA didnt do a little bit better given that the slowed I know you called out from timing issues on production how much of this was just kind of pacing, having a manufacturing campaign.
A broader.
Obviously off small base.
Yes, Hi title. This is Michael I'll take I'll take that question. Thanks, a couple of things to keep in mind for me Firstly, just relative magnitude of EMEA for us is roughly 5%.
And the way our portfolio has been built out there and skewed more towards the production environment and then two reasons that we participate in so we do see.
A little bit more volatility in Asia, owing to just a batch in campaign cycles that aren't that our customers.
Brings into.
And if you look at the third quarter, specifically in mild production.
In 2018 that was in fact, a high watermark for us in the region. There were a number of really really significant campaigns. We participated in that just based on the timing this year.
Several of those have actually slipped into the Q4 so.
I think structural.
You are still very well positioned there growth continues to be solid.
Look into the fourth quarter, and our order book, particularly around Bioproduction.
You'll see I think a return to kind of levels approach you would start to leverage.
Okay, and then lastly, just hopefully quick one, but how much EBITDA being lowered his FX versus accelerated growth spending.
The lower organic growth.
I think.
Yes, I mean, if you look at it if you look at at the midpoint Tiago.
We were at a tenfifty midpoint in the prior guidance or 10 30, now so call it 20 million.
20 million 15 is really the the Q3.
Results that we that we just took you through and the remainder is mostly FX for Q4.
Otherwise, we're pretty pretty in line with what we've talked about before Q4.
Okay. Thank you.
Our next question comes from the line of Derik de Bruin from Bank of America. Your line is open.
Hi, good morning.
I Wonder if I heard.
Hey, I just wanted to follow up on tight good question EBITDA.
The.
We realized a lot of FX.
Hi, good question.
Okay.
It's been a little bit more volatile than we thought.
Our.
Relative.
Your model was just curious.
Can you do through help knew that EBITDA.
Yes.
We do.
Okay.
2020.
Are you still comfortable.
At least 100 gig.
And next year current trends.
Yes.
Thanks, Derek I was having a little bit of difficulty hearing your first part of your question.
But if we if I talk about the trends going forward.
And you can start with the fourth quarter. If you look at our guidance for EBITDA. It does continue.
In line with the model that we've talked about just to remind you.
During the three year integration period of Turkey W.R.
And we have a high degree of confidence of being able to grow.
Margins in part because the conversion on organic growth, but also in part because of the synergies.
100, 150 basis point range, we did that for the first two quarters of this year, we'll do it for the fourth quarter.
Third quarter was for the reasons, we've talked about a little bit regression.
As you head into 2020, that's the third year of our three year integration.
And while we haven't finished our planning yet for.
2020.
I would expect.
We'll adjust the overall baseline to reflect 2019 actions, but the growth algorithm.
On an organic growth as well as margin expansion delevering and so forth still remain.
Yeah.
Can you help me can you take it back to the first part of the question.
No that basically that basically covers that that's that.
Got when I asked the first part on it I guess another question I just wanted to bring up was.
On you're seeing some good pricing gains and I.
And I'm just wondering how sustainable that is our junior seem little bit better pricing, even I would've thought you had can you talk about what you're doing just maintain that.
All right.
Eric as you look at the impact of pricing relative to volume I think the third quarter played out.
Plus or minus what we've seen in previous quarters, which is to say that we strive to modestly offset the cogs inflation that we do see in.
More transactional part of our portfolio and then.
More of our proprietary products, which tend to have more value based pricing approach to those.
Nothing really new to report there so.
As we look at the contribution of pricing in the quarter.
We call it out only to indicate that we continue to execute our model that we've had in place for quite some time here.
I don't think anything unusual turn to note there.
Right and just one other quick one if you look at.
You back out the onetime proprietary products, what did that grow in the quarter.
Yes, if you.
Yes, we were looking at the math on this morning, but if you take.
The impact of the besides an education piece of it.
We would have Ben.
Strong mid single digit like 5% to 6% is what you would have same which.
Certainly is.
Ted better than what you what we would have had on third party. So that we think the algorithm.
Probably terry growth relative to third party growth.
Still remains intact and that is a tenet of our of our baseline expansion.
Derek it's important when we look at the proprietary materials part of our portfolio.
In large part you're talking about our exposure to bile production, where most of our solution.
As manufactured.
From our own technologies.
And then our exposure into the health care space.
And with our medical grade Silicon platform is also an important part of that.
Algorithm that Tom mentioned and.
Point.
Those end markets for us continued to be very robust, we continue to see strong double digit growth in our bioproduction platform.
Led by.
More than 20% growth in our single use platform. So I would say it's important to recognize that.
The primary material part of our portfolio does influence margins due to large extends we've laid out today and a core part of that business continues to run at a very high level and save.
The one off here in the science education has talked about another really strong quarter.
Thanks for the clarity.
Our next question comes from the line of Jack Meehan from Barclays. Your line is open.
Thank you good morning.
Actually I wanted to follow good morning.
A follow up on last point, just as we look at the fourth quarter guidance it looks like around 5.5% organic.
What are you expecting proprietary to bounce back and Michael can you just say about that point related to maybe some of the proprietary products.
Cross GTB occur in new through just no.
Could you maybe how did they perform in the quarter and how are you feeling about that going into year end.
Right I guess sacrifice focus Jack when we look at the.
Deferred.
Q4 performance, obviously, you see strong topline.
Our return to kind of the normal margin expansion in line with our long range targets.
And then underneath all of that in order to happen, you're seeing a bounce back departure materials.
The way you right to think about that in the.
High single digit growth.
Gross levels for for Q4 and that is a part of our business. We've talked a lot about a limited visibility we have overall far order book.
Proprietary materials part is a.
Particularly in our about production space in area that does have a little bit longer lead times associated with it. So as we sit here in the first week of November we do have fairly good line of sight to orders that we would have through the end of year and are comfortable and kind of the guidance that we've that we put out for that aspect.
The model when I look into Q3, specifically around.
Production I referenced the strength of our safety Baker brands.
Bob production chemicals platform.
We use platform continues to grow.
Well into the double digits and well beyond.
I think any kind of normalized market growth rate for for this space, which.
I think speaks to our global presence and the success that we're having.
And going that part of our business.
You mentioned, the new cell business.
And Toms remarks, he did reference a bit of a pullback in that part of our portfolio as it relates to our healthcare business.
And that's another production oriented platform that you know from quarter to quarter can have.
Little bit of volatility to its just given the production cycles and inventory balancing that our customers.
We'll go through.
Particular platform Q3, a year ago was the high watermark I think we grew that platform, 25% a year ago. So you see a bit of a more normalized environment.
Third quarter this year.
On the comp loosens up a bit and we see structurally.
Our return to normal growth in that and market as well.
Great. Thanks for all the corner and then in the slide deck I really like the EBITDA bridge on slide eight but the one thing I guess that to me was that net productivity was only half and then in terms of the year over year.
Contribution.
$247 million elementary synergy even annualized some of these formal as you go into the numbers, but.
How much.
As we exit 2019 and go into 2020 can you give us a sense for how much is left in terms of the potential to expand margins based on synergies.
Right. So I think I'll provide a little bit high level cover for your question. There and then Tom will give you specific walk on that net productivity element of the bridge.
We're still very confident and delivering the $300 million of synergies that we outlined at the beginning of the integration DWR and were run rating nearly 250 million at the end of.
The quarter here and as we look forward into next year and the individual programs that are in line.
I guess two to 300 I would say, we're very very confident about that one important point to notes.
You know that program is comprised of literally hundreds of individual projects some of which are driving topline revenue. Some that are driving reduction in cogs. Some that are more SGN aid driven so you're going to see the impact of that 300 million scattered throughout.
The PM now.
And as we look into.
The balance of this year and moving into next year, you'll continue to see a step up in the contribution from.
From that program now what we're reflecting here in the bridge and Tom will walk you through it is just kind of a netting of on the.
Cogs side of Canada fixed cost side of things how that productivity plays out in a quarter, yes. So just to get right to the productivity number that you saw in there I mean, it does look a little more easily in the in the walk, but it really is a reflection of.
Some very strong performance on the value capture I mean, there too.
This has the SJ.
Synergies and productivity that we deliver the corporate it was approaching $10 million.
What I'd say.
Yes, theres additional synergies and productivity that's embedded in the price volume line for the part of the.
Synergy is the value capture and synergies that are in the operating piece of the business, but just from an M&A perspective in this net productivity, you've got 10 million offset by some big investments we made.
Investments in.
Asia in particular is we're continuing to.
Invest in feed on the Street and then.
Laboratory capabilities.
We've also got.
Some additional investments elsewhere in the enterprise just growth oriented R&D kind of investments and you had a little bit of inflation.
In there as well from a year over year perspective so.
I expect the that bar to get bigger as we head into fourth quarter and into 2000 in 2020.
Thank you Beth.
Our next question comes from the line Vijay Kumar from Evercore ISI. Your line is open.
Hey, guys. Thanks for taking my question, so maybe I'll.
I'll start with this up Q4, five six just given Q3 was a little bit like maybe talk about.
The drivers here I know the comp it's easy for Q4.
Your next the comp anything that we should be aware off the confidence if you havent, 5% to 6% for Q4.
Yes, I mean, Jay Thanks for question good morning.
I think when you it's important to kind of grounded in Q3, I think you're looking at a quarter here that really did want to be 5% on its own absent. This.
One time issue with.
The science education.
Customer that doesn't repeat going into the quarter, So you're looking at a normalized.
Digital.
Growth as launching point from Q3 going into Q4.
The comp does pull back a couple hundred basis points.
We've had a number of recent contract wins.
We've got obviously visibility as I referenced earlier into the campaign schedules of medium or large newbuild production customers, especially in Asia, which will.
Print into the quarter here, so as we look at.
Kind of an inferred Q4 here in that five to six.
You know range. It also has the embedded or implied.
Normal year end budget flush that we would see in our consumables business.
And so I think we're we're comfortable with the trends that we've seen exiting September early read on October will be supportive of the guidance that we have in mind here in.
Rounded out with a pretty robust order book or Bioproduction.
That's helpful. And then maybe one enough free cash flow Tom I think the presentation had you guys.
De levering to sub four turns into fiscal 2008, Youre at 4.8 that right now.
I mean, basically what 550 million of free cash guidance for the year. This is implying your free cash flows should grow north of 40% due to pay down an incremental bill enough debt between now and now end of fiscal 2000 is that does it make sense. Your free cash by 54, 19 that should be catering at 40% of growing 40.
And for next year.
So we will you have to factor in the EBITDA growth it will get us well on the de levering.
So I haven't done the math on that but it is a combination of.
The growth in the EBITDA as well as they continue we continued servicing on the debt.
Yes.
That's an impressive free cash flow growth number guys. Thanks.
Our next question comes from the line of Brandon Couillard from Jefferies. Your line is open.
Thanks, Good morning.
Hey, good one Ren.
Mike If you look the industrial markets globally in the third quarter could you just kind of unpack the various sub segments globally, particularly on the more cyclical C.
Chemical and industrial side, and what you're embedding for that market in Fourq.
Right. So just maybe to provide a little bit of context here.
Roughly 25% of our revenue would have exposure into this industrial.
End market, but in a very fragmented way, we're going to serve lots of different applications, whether that be aerospace and defense semiconductor space food and beverage oil and gas.
With no end markets, representing more than kind of low single digit percentage of our of our overall revenue.
And as we have been signaling for most of the year. This part of our business has been relatively soft.
To to negative and.
Certainly haven't really seen a significant change in that trajectory in the third quarter and nor are we anticipating.
Or relying on any significant pickup in that and of those end markets in the fourth quarter. There are a couple of pockets of bright spot for us our exposure the aerospace and defense end market is rather unique in that were specked in much. The same way you would expect us to be.
Back into a biologic drug with a very specific specification I long term platform.
That.
Is growing certainly grew in the third quarter, and we'll continue to grow going into fourth quarter.
The semiconductor space is another important end market for us.
And we've seen.
The business in Asia slide for most of the year.
Starting to moderate a bit in the third quarter I would say in.
We feel like we've probably bottomed out.
In Asia in that end market and see.
The signs of a little bit of an uptick nothing.
That will drive the results significant way, but certainly a glimmer of hope that things have likely bottomed out there.
Europe when you look at an impressive print there on the quarter of 4.5%.
It is still.
One or 200 basis points below where we had been running earlier in the year and I would say if there was one change I would point out we did see kind of the industrial end markets in Europe .
I'll start to slow down a bit in the third quarter and I think when you look at.
4.5% print that obviously demonstrates the.
Exposure, we have to Biopharma in Europe , but it also does reflect a little bit of a weakening environment in Europe across the industrial sector.
Particularly as it relates to capital expenditures.
And if you recall roughly 15% of our portfolio.
In the equipment has been part of what we offer is going to be subject to our customers capital expenditure programs and certainly saw tightening of that in Europe , we were off in the quarter.
No single digits on that.
On that platform.
And.
See that kind of moderating here through the through the fourth quarter. So I would say continued weakness with maybe a couple areas a bright spot in I would say Europe had a few more headwinds in the third quarter than what we can see.
Up to that point in the year.
Thanks I appreciate the color then Tom just from the guide Truman EBITDA a little bit.
For the year, just curious if but holding GPS just curious if there any changes below the line in terms of net interest and other or tax for the year. Thanks.
Not really I mean, when we we put together the the original guide.
We had some some assume levels as the interest expense, we've done a little bit better.
On that as we progress through the early we had.
Repricing.
In the in the middle of the year, that's helped a little bit we've also.
The IPO was a little bit bigger than than we had modeled.
So between those two we're getting some favorability on the on the interest lives taxes will be pretty pretty much in line with.
It was what we modeled out in that 30% range.
Talked about as we as we look forward to tax I mean, thats certainly an area of opportunity for us.
We're making good progress on some of the things we need to do to bring that that rate down to levels I've talked about before but the overall.
It's not it's not a significant.
No change other than the factors I mentioned at the repricing in the IPO side.
Super Thank you.
Our next question comes from the line of Doug Schenkel from Cowen Your line is open.
Hey, good morning, guys.
Maybe just maybe to start with a.
I guess sort of a high level question as you noted in your prepared remarks, and as we've covered a bunch of times already over the course of this call.
You had some onetimers and generally speaking a tough comparison relative to the norm in the quarter that depressed organic revenue growth relative to recent trend.
That said it does seem like somewhat surprised you in the quarter given that you've cut full year guidance.
Thats basic but I just want to make sure that's fair.
And building off of that probably more importantly.
Even if something changed relative to your internal model for the second half of this year is it fair to say that youre, 5% to 8% long term revenue growth guidance is very much intact at this point.
Yes, let me take that.
Question.
I think your observations on some of those onetime nature of.
The results that we saw here.
We are somewhat to be expected certainly the tough comp was known certainly.
The shifting of revenue from from Q3 Q2 from this assigns indication customers.
What was not known is on that part of the business.
Was the relative level of inventory that they were carrying and.
The the.
The volume that Didnt repeat in the quarter. So we knew that there was a pull forward of some of the volume, but there was.
Lack of transparency on just how much.
Inventory that they were carrying and then as a consequence volume would repeat in the quarter the other.
Dynamic that we didnt anticipate going into the quarter and this is actually relatively.
Our normal for that end market, but in the healthcare space relatively limited visibility into.
Inventory through the supply chain, you do have relatively volatile production schedules and coming off a quarter, where we had 25% revenue a year ago.
Knowing at some point that there would be likely some inventory taken out of.
On the value chain, the timing of which is very difficult to predict and unfortunately, it looked like more of it came out in Q3 than what we would have and anticipated. So those are probably the two things that I would point to.
The that.
Surprised us a bit on the quarter relative to.
Kind of our longer term guide absent those two factors, we had a great quarter.
Our consumables business.
Holding up in the mid single digit levels are bioproduction business holding up in the low double digit range.
Model, that's really built to deliver over the long term on a sustainable basis mid single digit growth.
With the embedded.
Power.
On various quarters as we've demonstrated to go even into the high single digit range is very much intact.
And you see that optimism we have here around our our fourth quarter.
Okay. That's all Super helpful and maybe if I could just slip in one quick follow up.
On tax rate you came in well below expectations in the quarter.
How much of that.
A function of timing or something else and I guess as we look ahead do you still expect 2020 adjusted tax rate to be in the 26% to 27% range or are you seeing something as we sit here today that could drive that even lower. Thank you, yes, yes, I think I think when you're talking about Doug is for everybody's references.
Our guide for for the tax for the year is roughly 30%, we're still sticking to that.
The quarter was a little bit lighter in terms of.
In terms of the rate at it came at around 27%, that's about two and half million of of net income.
Yes, less less than a penny.
So not not terribly material and there's really nothing to point to structurally or from a longer term perspective, but I would say that.
And repeat what I said earlier that we are on track relative to things that we need to do to get that the tax rate lined up for two.
2020, particularly around the way we're financing our international operations doing that.
Much more tax efficient.
Manner.
Okay, that's great Super helpful. Thank you.
Our next question comes from the line of Dan Brennan from.
Your line is open.
Great. Thank you thanks for taking the questions.
I joined a little late I'd first question would just on Amy.
The smaller portion of your business, but I know, it's an important growth opportunity for you in the growth. This quarter was below what we were expecting so could you just kind of give us some sense of.
Kind of what the trend wasn't in the quarter and also as we look out.
What's the right kind of growth rate to expect for that geography.
And then we discovered that.
Yes, we did cover that question earlier in the call here, but just to reiterate the key points from let me answer we gave there.
Obviously, it's a relatively smaller modest.
Revenue base for Us in Asia, roughly 5% of our overall revenues.
Unlike the other two regions that we serve.
It's disproportionately oriented towards our production customers and then naturally.
The exposure to their their campaigns cycles. So we've had a number of really important wins in the region. This year.
It just so happens that last year was probably the high watermark for.
Production business in the region, a year ago, some very difficult comps and a number of those campaigns actually slowed in the fourth quarter for this year, so nothing particularly structural.
Business continues to perform.
Certainly muted by.
Downsizing, our electronic materials platform continues to be to be negative.
But long term, we would expect that.
As part of our business to grow.
Just in a low double digit range civil future.
And then and Michael Thank you for that and then and then just within Biopharma there's been.
Kind of varying degrees of kind of growth this quarter from your peers across the different sub segments within biopharm, but just.
The growth this quarter was still positive look a little bit lower than what it had been just can you kind of remind us of kind of your split within biopharma between the by production, which is obviously a robust and other areas and how we think about the trajectory of Biopharma in Q4 and beyond thank you.
So biopharma for US is roughly 50% of our revenues obviously is a critical end market for us and we're excited about the momentum that we have in the business, we highlighted a number of.
Customer wins that we had in the quarter.
Which would be a follow on from a number of specifications and win wins that we've had throughout the year. So really great momentum there we're going to serve biopharma across the workflows starting in the research and discovery phase all the way through to the production environments as a rule of thumb, you probably wouldn't be too far off to assume roughly two thirds of that run.
Who is going to fall into the laboratory and research and discovery phase and somewhere in the range of a third of the revenue falling into the production environment clearly the growth in production piece of that is going to be a bit more robust I.
I think if you look good and triangulate most of the market data points on file production growing high single digits low double digits.
Given our portfolio our exposure globally, we would expect to do at least in line with that is not.
Not slightly better than that.
Great. Thank you.
Our next question comes from the line of Aaron right from Credit Suisse. Your line is open.
Great. Thanks.
Some of the nature of those contract wins in the quarter.
The integrated offering.
The wins across your ROE.
From.
There.
Hello.
Yes, no worries excited too.
To speak about some of the success that we're having.
No we won't get any specific customer ditto for obvious reasons here, but when I look at the success that we've had in defending our accounts as well as.
Winning new accounts across Biopharma.
Across as education, especially it's been a it's been really successful year.
And when I speak to our customers on the back into these discussions you know two or three things seem to meet with them.
Juan the power of our integrated offering is certainly unique for them and these two platforms have come together, we're able to offer them.
Much more significant solution today than we ever how before and you see that.
No.
Our share of wallet that we're able to gain with some of these accounts our global exposure is important we referenced in our remarks.
One example of a customer that we historically when we served in.
In Europe , but as we have built out our capabilities, especially in Asia, but.
So building on our.
Presence in the Americas, they stepped up and worried about business to us globally.
Aerospace continues to be important.
And driver of growth for US we had a number of important contract wins in the quarter in that space and then playing on the theme that we've been running now for multiple quarters. We continue to build momentum in our higher education portion of our business in the Americas, We had.
We have as we've discussed and.
Other forums.
An exclusive relationship with.
A consortium organization that a lot of the universities as part of the world, we buy across and given that position as well as just the focused efforts that we've been driving.
We've seen a number of important contract wins in higher education space. This year.
Great. Thanks.
Taking a little deeper into the DWR synergies I guess can you give that the geographic.
Hi.
They are specifically in.
That was an area that you highlighted.
With that.
Opportunity.
Right.
Well that.
There.
That is when we look at synergies.
Two thirds cost roughly one third.
Commercial synergies.
Good bit of those commercial synergies actually play out in Asia, as you're describing as we integrate VR portfolio across in that case, what happens within the legacy onto our infrastructure and we continue to invest in you see that in some of our us unit numbers and other.
Operating expenses, whether that be and.
Sales reps or marketing resources or were commercializing new application center that will open here in a few weeks in Shanghai. So we'll continue to build out.
Supply chain to service that.
And to be able to capture those those synergies.
But they definitely.
As we see out over the long term.
Our region that we growing double digits in part due to these you synergies.
Yes.
Thank you I would now like to turn the call back over to Mike will double fields for closing remarks.
Yes. Thank you everyone for participating in our call today, we certainly appreciate your support of of of onboard as we've talked here, we had a bit of noise in the quarters from some prior year, one awesome and mix and foreign currency headwinds, but.
We're pleased with the underlying growth that we did generate strong cash generation excited about the optionality that.
Leveraging trend that we have will provide for our business going forward.
Alpharma.
Our certainly are most important end market.
Continues to grow strong and overall, we exited September with with great momentum that has carried forward into fourth quarter.
We talked on the call today, we did see significant customer wins in the quarter and were.
You know strengthening our overall value proposition by continuing to make strategic investments to better serve our customers.
Our operating performance benefited from continued progress in the operational efficiencies and synergies from our integration program would be W.R. and overall, we remain on track to deliver the margin expansion in cash flow. That's in line with our long term objectives.
As we look at this platform or our business is well positioned to further in April .
Innovation breakthroughs that help our life science customers dramatically.
Patient outcomes.
Again I appreciate you joining our call today, we look forward to our next update.
After the new year and seeing some of you in person in coming weeks upgrade to everyone. Thank you.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating you may now disconnect.